Casey Murray Joseph, Synder Carrie, Bewtra Chhanda, Narod Steven A, Watson Patrice, Lynch Henry T
Department of Obstetrics and Gynecology, Creighton University School of Medicine and the Creighton Hereditary Cancer Institute, Creighton University Medical Center, 601 North 30th Street, Suite 4700, Omaha, NE 68131, USA.
Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039.
Prophylactic surgical removal of the ovaries has been offered for many years as a potential preventative of ovarian cancer in women deemed to be at increased hereditary risk for this disease. Now, it is possible to test for specific mutations of the BRCA1 and BRCA2 genes that render members of hereditary breast ovarian cancer (HBOC) syndrome families susceptible to cancer. Widespread intra-abdominal carcinomatosis, which mimics metastatic ovarian serous carcinoma, has been reported following oophorectomy in individuals at increased hereditary risk. This study was undertaken to examine and report particularly the occurrence of intra-abdominal carcinomatosis, as well as other cancers, following prophylactic oophorectomy in patients who carry cancer susceptibility mutations of BRCA1 and BRCA2 and to assess the cumulative risks for this disease in order to assist in developing appropriate surgical interventions, based on currently available information, and to counsel patients who choose prophylactic surgery, concerning the potential prognosis, thereafter.
The Creighton University Hereditary Cancer Institute registry was searched for members of HBOC syndrome families who had undergone prophylactic oophorectomy. The histories and results of DNA testing for the BRCA1 and BRCA2 mutations carried in their families were recorded, tabulated and examined, and the aggregate data are reported along with pertinent details of those individuals who developed neoplastic diseases after prophylactic oophorectomy. All available histologic and cytologic materials of patients who were diagnosed with intra-abdominal carcinomatosis were reviewed, and life-table calculations were performed to assess cumulative risks for this disease following prophylactic oophorectomy.
From 72 HBOC syndrome families that carried either BRCA1 or BRCA2 cancer-associated mutations, 238 individuals who had undergone prophylactic oophorectomy were recorded in our registry between January 1985 and December 2002. During a mean follow-up of 9.3 years, cancers were diagnosed in 27 subjects, including 16 individuals with breast cancer and five patients with intra-abdominal carcinomatosis. Breast cancers were stage I in 10 of 12 proven carriers of cancer-associated mutations. All five cases of intra-abdominal carcinomatosis were serous carcinomas, and all occurred in BRCA1 mutation carriers. Histologic review of the prophylactically removed ovaries found borderline lesions in two cases, one with possible early stromal invasion. Two of the five patients who developed intra-abdominal carcinomatosis were among 78 patients in this series who were diagnosed and treated for breast cancer before prophylactic oophorectomy. A 3.5% cumulative risk for all mutation carriers and a 3.9% cumulative risk for BRCA1 mutation carriers were calculated through 20 years of follow-up after prophylactic oophorectomy.
Intra-abdominal carcinomatosis in our series was diagnosed only in BRCA1 mutation carriers. The calculated cumulative risks of developing intra-abdominal carcinomatosis after prophylactic oophorectomy in members of HBOC syndrome families, specifically those who carry deleterious mutations, are well below the estimated risks of ovarian cancer published in the literature for similar patients. Breast cancers, which tended to be small and localized, were the most common malignancy in BRCA1 and BRCA2 mutation carriers after prophylactic oophorectomy.
多年来,对于被认为遗传性卵巢癌风险增加的女性,预防性手术切除卵巢一直被视为预防卵巢癌的一种潜在手段。现在,可以检测BRCA1和BRCA2基因的特定突变,这些突变使遗传性乳腺癌卵巢癌(HBOC)综合征家族成员易患癌症。据报道,遗传性风险增加的个体在进行卵巢切除术后出现了广泛的腹腔内癌病,类似于转移性卵巢浆液性癌。本研究旨在特别检查和报告携带BRCA1和BRCA2癌症易感性突变的患者在预防性卵巢切除术后腹腔内癌病以及其他癌症的发生情况,并根据现有信息评估该疾病的累积风险,以协助制定适当的手术干预措施,并就潜在预后向选择预防性手术的患者提供咨询。
在克里顿大学遗传性癌症研究所登记处搜索接受过预防性卵巢切除术的HBOC综合征家族成员。记录、列表并检查其家族中携带的BRCA1和BRCA2突变的DNA检测历史和结果,并报告汇总数据以及预防性卵巢切除术后发生肿瘤性疾病的个体的相关详细信息。对所有被诊断为腹腔内癌病的患者的可用组织学和细胞学材料进行了复查,并进行了生命表计算以评估预防性卵巢切除术后该疾病的累积风险。
在1985年1月至2002年12月期间,我们的登记处记录了来自72个携带BRCA1或BRCA2癌症相关突变的HBOC综合征家族的238名接受过预防性卵巢切除术的个体。在平均9.3年的随访期间,27名受试者被诊断出患有癌症,其中包括16名乳腺癌患者和5名腹腔内癌病患者。在12名经证实的癌症相关突变携带者中,10例乳腺癌为I期。所有5例腹腔内癌病均为浆液性癌,且均发生在BRCA1突变携带者中。对预防性切除的卵巢进行组织学检查发现2例有交界性病变,其中1例可能有早期间质浸润。发生腹腔内癌病的5名患者中有2名是该系列中78名在预防性卵巢切除术前被诊断并接受乳腺癌治疗的患者。通过预防性卵巢切除术后20年的随访计算出,所有突变携带者的累积风险为3.5%,BRCA1突变携带者的累积风险为3.9%。
我们系列中的腹腔内癌病仅在BRCA1突变携带者中被诊断出。HBOC综合征家族成员,特别是那些携带有害突变的成员,在预防性卵巢切除术后发生腹腔内癌病的计算累积风险远低于文献中报道的类似患者的卵巢癌估计风险。乳腺癌往往较小且局限,是BRCA1和BRCA2突变携带者在预防性卵巢切除术后最常见的恶性肿瘤。